<DOC>
	<DOCNO>NCT00464620</DOCNO>
	<brief_summary>This study examine response rate 6-month progression-free survival rate subject advance sarcoma treat dasatinib .</brief_summary>
	<brief_title>Trial Dasatinib Advanced Sarcomas</brief_title>
	<detailed_description>Further detail provide SARC ( Sarcoma Alliance Research Collaboration ) : Treatment : Subjects take Dasatinib twice daily mouth 28 day per 28 day cycle . Subjects see interim medical history , physical exam laboratory study prior cycle . Subjects undergo tumor image every 2 month ( 8 week ) first 6 month approximately every 3 month thereafter treatment . A blood sample collection specimens later study serum level Dasatinib effect biomarkers drug activity obtain approximately 2 4 week start treatment . Central collection archival tumor later study frequency expression and/or mutation kinase inhibit dasatinib occur . Subjects follow approximately every 3 month 2 year registration approximately yearly 5 year registration .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Chordoma</mesh_term>
	<mesh_term>Hemangiopericytoma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Giant Cell Tumor Bone</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Sarcoma , Alveolar Soft Part</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Unresectable , recurrent , metastatic histologicallyconfirmed soft tissue bone sarcoma one follow subtypes : Leiomyosarcoma * NO LONGER ELIGIBLE* Liposarcoma* NO LONGER ELIGIBLE* Malignant fibrous histiocytoma ( MFH ) /pleomorphic undifferentiated sarcoma* NO LONGER ELIGIBLE* Rhabdomyosarcoma * NO LONGER ELIGIBLE* Malignant peripheral nerve sheath tumor ( MPNST ) * NO LONGER ELIGIBLE* Osteosarcoma ( skeletal extraosseous ) * NO LONGER ELIGIBLE* Ewing 's * NO LONGER ELIGIBLE* Chondrosarcoma Alveolar soft part sarcoma Chordoma Epithelioid sarcoma Giant cell tumor bone Hemangiopericytoma/solitary fibrous tumor Gastrointestinal Stromal Tumor ( GIST ) * NO LONGER ELIGIBLE* 2 . Documentation subject leiomyosarcoma , liposarcoma , osteosarcoma , Ewing 's , MPNST , rhabdomyosarcoma MFH receive , eligible refuse least one prior chemotherapy regimen participation dasatinib study . Subjects GIST must receive intolerant imatinib ; prior treatment agent include sunitinib required.Neoadjuvant/adjuvant chemotherapy qualifies prior therapy . 3 . Subjects must unidimensionally measurable lesion ( ) either xray , compute tomography ( CT ) , magnetic resonance imaging ( MRI ) physical examination document within 30 day prior registration . 4 . Prior radiation allow . More two week elapse since administration last fraction radiation therapy , subject must recover grade 2 high associate toxicity . Measurable lesion , select target lesion , must outside previously radiate field document progression sooner 6 week completion radiation . 5 . More 2 week must elapse since subject receive prior systemic chemotherapy ( 6 week mitomycin C ) , patient recover toxicity baseline prior last course chemotherapy . 6 . Adequate hematologic function within 14 day prior registration . 7 . PT ( INR ) PTT ≤ 1.5 time institutional ULN within 14 day prior registration . 8 . Serum creatinine ≤ 2.0 time institutional ULN within 14 day prior registration . 9 . Serum magnesium , potassium adjust ( ionize ) calcium ≥ institutional LLN . ( Supplementation electrolytes prior screen allow ) . 10 . Left ventricular ejection fraction ≥ 45 % measure echocardiogram multiple gate acquisition ( MUGA ) within 30 day prior registration ( must perform last dose anthracycline ) subject receive anthracycline ( e.g . doxorubicin , epirubicin ) medical history cardiac disease . The measurement leave ventricular ejection fraction require subject receive cardiotoxic chemotherapy ( e.g . anthracycline ) medical history cardiac disease . 11 . Sexually active woman men childbearing potential must agree use effective method birth control course study 3 month follow last dose study drug , manner risk pregnancy minimize . Surgical sterilization , intrauterine device barrier method ( e.g . condom and/or diaphragm spermicidal agent ) acceptable form birth control . 12 . Women childbearing potential must negative pregnancy test ( urine serum ) within 7 day prior treatment . A pregnancy test require registration . Women menstruate 2 year consider postmenopausal , thus childbearing potential . 13 . ECOG performance score 0 , 1 2 . 14 . Weight ≥ 50 kg limit experience dasatinib subject weigh less 50 kg . 15 . ≥13 year age Minors require sign assent document prior treatment . 16 . Subjects must able swallow whole tablet . 17 . Subjects must inform investigational nature study provide write , informed consent authorization release protect health information use document ( ) approve investigator 's institution . 18 . A paraffin block , either previous surgery recent biopsy , available correlative study . If block tumor available , least 8 unstained slide tumor sample , 1 H &amp; E three ( 3 ) 15 micronthick section eppendorf tube DNA extraction representative portion sarcoma may substitute discussion approval study Principal Investigator . 1 . Subjects curable conventional multidisciplinary management . 2 . Subjects symptomatic central nervous system metastasis . 3 . Women pregnant nursing/breastfeeding . 4 . History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) 5 . Subjects currently take medication inhibit platelet function ( i.e. , aspirin , dipyridamole , epoprostenol , eptifibatide , clopidogrel , cilostazol , abciximab , ticlopidine , nonsteroidal antiinflammatory drug ) potential increase risk bleeding dasatinib . 6 . Subjects currently take anticoagulant ( warfarin , heparin/low molecular weight heparin [ e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ] ) potential increase risk bleeding dasatinib . 7 . Diagnosis unstable angina myocardial infarction within 6 month study entry . 8 . Subjects currently take one follow drug generally accept risk cause Torsades de Pointes : Quinidine , procainamide , disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycins , clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide Cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . 9 . Diagnosed suspected congenital long QT syndrome . 10 . Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) within 30 day prior study registration . 11 . Subjects unable unwilling suspend treatment bisphosphonates least first 8 week treatment study drug risk hypocalcemia cause dasatinib .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dasatinib</keyword>
	<keyword>Rhabdomyosarcoma</keyword>
	<keyword>Malignant peripheral nerve sheath tumor</keyword>
	<keyword>Chondrosarcoma</keyword>
	<keyword>Ewing 's</keyword>
	<keyword>Alveolar soft part sarcoma ( ASPS )</keyword>
	<keyword>Chordoma</keyword>
	<keyword>Epithelioid sarcoma</keyword>
	<keyword>Giant cell tumor bone</keyword>
	<keyword>Hemangiopericytoma/solitary fibrous tumor</keyword>
	<keyword>Gastrointestinal Stromal Tumor ( GIST )</keyword>
</DOC>